ETFA

ETFA encodes a mitochondrial protein that directly participates in cellular energy (ATP) production, a role demonstrated when a small-molecule PROTAC that binds and thermally stabilizes ETFA enhanced ETFA-mediated ATP generation in NSCLC cells (PMID:40815992). Beyond its bioenergetic function, ETFA serves as a downstream effector in stress and disease pathways: in cardiomyocytes the transcription factor Irx3 directly binds the Etfa promoter and upregulates its expression, and this Irx3–Etfa axis suppresses ferroptosis and attenuates pathological cardiac hypertrophy, with Etfa knockdown abolishing the cardioprotective effect of Irx3 (PMID:41631390). ETFA expression is regulated at the promoter level by multiple inputs, including EZH2-mediated promoter methylation in colorectal cancer cells (PMID:34405537) and post-transcriptional targeting of ETFA mRNA by miR-320b in endothelial cells (PMID:38556340). A homozygous ETFA promoter variant (c.-85G>A) reduces promoter activity and ETFA protein, establishing that intact ETFA expression is required to prevent multiple acyl-CoA dehydrogenase deficiency (MADD) (PMID:36579410). Detailed enzymatic and structural characterization of ETFA's role in mitochondrial electron transfer has not been described in the available corpus.

1. 2021 Medium

   Established that ETFA expression is epigenetically controlled, identifying EZH2-mediated promoter methylation as an activating input subject to lncRNA regulation.

   Evidence RNA pull-down, RIP, luciferase, and silencing/overexpression in colorectal cancer cell lines

   PMID:34405537

   Open questions at the time

   • Does not test the bioenergetic or metabolic consequences of altered ETFA levels
   • Promoter methylation-mediated activation not independently replicated
2. 2022 Medium

   Demonstrated that the ETFA promoter region is functionally required for normal expression, linking promoter disruption directly to MADD pathology.

   Evidence Whole genome sequencing of a patient, promoter luciferase reporter assay, and Western blot of lymphoblasts

   PMID:36579410

   Open questions at the time

   • Single family/variant
   • Does not resolve the downstream enzymatic defect at the protein level
3. 2024 Low

   Identified post-transcriptional control of ETFA by miR-320b in endothelial cells, connecting ETFA levels to oxidative stress and inflammatory output under hypoxia.

   Evidence miRNA mimic/knockdown, Western blot, and proliferation/migration assays in CoCl2-treated HUVECs

   PMID:38556340

   Open questions at the time

   • Direct 3'UTR luciferase validation of ETFA as a miR-320b target not explicitly confirmed
   • Target relationship inferred from expression changes
   • Single lab
4. 2025 Medium

   Provided direct evidence that ETFA protein drives ATP/energy production, showing a small molecule that stabilizes ETFA enhances its bioenergetic function.

   Evidence Thermal shift (CETSA-type) binding assay, cellular energy production assays, and xenograft model in EGFR-TKI-resistant NSCLC

   PMID:40815992

   Open questions at the time

   • Mechanism of how ETFA stabilization increases ATP not resolved at the enzymatic level
   • Single study
5. 2026 Medium

   Placed ETFA as a direct transcriptional target and effector of Irx3 that suppresses ferroptosis and cardiac hypertrophy, defining a protective signaling axis.

   Evidence AAV overexpression/knockdown in TAC mouse and angiotensin II cardiomyocyte models, promoter binding assay, and transcriptomics with ferroptosis markers

   PMID:41631390

   Open questions at the time

   • Molecular link between ETFA bioenergetic function and ferroptosis suppression unresolved
   • Single lab

• The biochemical mechanism by which ETFA mediates mitochondrial electron transfer and how its energy function connects to ferroptosis and MADD pathology remains uncharacterized in this corpus.
• No structural model or enzymatic characterization in the timeline
• No identified direct protein partners in the electron transfer chain